openPR Logo
Press release

Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

09-18-2017 08:52 AM CET | Health & Medicine

Press release from: Arizton Advisory & Intelligence

Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017

The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations.

View report: https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights

It also assesses the pipeline HDAC inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides detailed information about discontinued and dormant drugs.

The report profiles key players in developing potential HDAC drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

Scope

Provides in-depth insights about active Histone Deacetylase (HDAC) inhibitors pipeline drug candidates

Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery

Provides pipeline assessment by monotherapy, combination therapy products, and route of administration

Provides comparative analysis of key marketed and pipeline Histone Deacetylase (HDAC) inhibitors

Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development partner

Analyzes key players involved in clinical research and development of the HDAC inhibitors

Provides the coverage of key news related to HDAC inhibitors, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.

Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017 here

News-ID: 721765 • Views: 179

More Releases from Arizton Advisory & Intelligence

Nurse Call Systems Market Size to Reach Revenues of USD 2.7 Billion by 2025 – …
In-depth analysis and data-driven insights on the impact of COVID-19 included in this global nurse call systems market report. The global nurse call systems market is expected to grow at a CAGR of around 11% during the period 2019−2025. Key Highlights Offered in the Report: 1. The increasing need for healthcare services and the rising influx of COVID-19 cases have resulted in the expansion of healthcare infrastructure and a demand for
Drug-Coated Balloons Market Size to Reach Revenues of USD 1.5 Billion by 2025 …
In-depth analysis and data-driven insights on the impact of COVID-19 included in this global drug-coated balloons market report. The global drug-coated balloons market is expected to grow at a CAGR of over 15% during the period 2019−2025. Key Highlights Offered in the Report: 1. The global drug-coated balloons (DCBs) market is expected to reach above USD 1.5 billion by 2025 with high double-digit growth rate of around 15% over the forecast
APAC Data Center Colocation Market Size to Reach Revenues of USD 8.4 Billion by …
The APAC data center colocation market size is expected to grow at a CAGR of over 5% during the period 2019−2025. Key Highlights Offered in the Report: 1. Over 40 million square feet of data center space will be added by colocation service providers in APAC during 2019-2025. 2. The APAC colocation market witnessed investments in over 110 data center projects in 2019. 3. Colocation services revenue in APAC is expected to
Vital Signs Monitoring Devices Market Size to Reach Revenues of over USD 15 Bill …
In-depth analysis and data-driven insights on the impact of COVID-19 included in this global vital signs monitoring devices market report. The global vital signs monitoring devices market is expected to grow at a CAGR of over 8% during the period 2019−2025. Key Highlights Offered in the Report: 1. The global vital signs monitoring devices market is growing at a significant rate and is expected to witness an absolute growth of around

All 5 Releases


More Releases for HDAC

HDAC Inhibitors Market - Future and Technological Advancement 2026
HDAC inhibitors refers to the class of anti-cancer agents that play a vital role in non-epigenetic or epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone deacetylase inhibitors (HDACi) are promising therapeutics, which have already shown potential for oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Vorinostat (Merck & Co. Inc.) is a novel drug used in the management of cutaneous T cell
HDAC Inhibitors Market - Trends and Opportunities 2017 - 2025
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur
Global Histone Deacetylase(HDAC) Inhibitors Market 2017 - SpeBio, Onyx, Quimatry …
Apex Market Reports, recently published a detailed market research study focused on the "Histone Deacetylase(HDAC) Inhibitors Market" across the global, regional and country level. The report provides 360° analysis of "Histone Deacetylase(HDAC) Inhibitors Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Histone Deacetylase(HDAC) Inhibitors industry, and estimates the future trend of
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitor Market Research Report 2017
Reports And Markets Publish a New Market Research Report On –"Histone Deacetylase (HDAC) Inhibitor Market Research Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-histone-deacetylase-hdac-inhibitor-market-research-report-2017-1541214 In this report, the global Histone Deacetylase (HDAC) Inhibitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented